Performance of the UK prospective diabetes study risk engine and the framingham risk equations in estimating cardiovascular disease in the EPIC- norfolk cohort

Diabetes Care

Volumn 32, Issue 4, 2009, Pages 708-713

  Simmons, Rebecca K ^a   Coleman, Ruth L ^b   Price, Hermione C ^b   Holman, Rury R ^b   Khaw, Kay Tee ^c   Wareham, Nicholas J ^a   Griffin, Simon J ^a  

^a MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PERFORMANCE; PROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GREAT BRITAIN; HEALTH STATUS; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS;

EID: 65349174438     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1918     Document Type: Article

References (22)

1. Panzram G: Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123-131, 1987
2. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton- Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
4. Ramachandran S, French JM, Vander- pump MP, Croft P, Neary RH: Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ 320:676-677, 2000
5. Brindle P, Beswick A, Fahey T, Ebrahim S: Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92: 1752-1759, 2006
6. Coleman RL, Stevens RJ, Retnakaran R, Holman RR: Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 30:12921293, 2007
7. Coleman R, Stevens R, Holman R: The Oxford Risk Engine: a cardiovascular risk calculator for individuals with or without type 2 diabetes. Diabetes 56 (Suppl. 1):A170
8. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30:1638-1646, 2007
9. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N: EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80 (Suppl. 1):95-103, 1999
10. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, Hack CE, Reitsma PH, Khaw KT: Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPICNorfolk Prospective Population study. Am J Med 117:390-397, 2004
11. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743-753, 2008
12. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837-845, 1988
13. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, discussion 207-212, 2008
14. Stevens RJ, Kothari V, Adler AI, Stratton IM: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101: 671-679, 2001
15. McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P, Currie CJ: Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 21:318323, 2004
16. Yeo WW, Yeo KR: Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341-344, 2001
17. Stevens RJ, Coleman RL, Holman RR: Framingham risk equations underestimate coronary heart disease risk in diabetes. Diabet Med 22: 228, 2005
18. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD: Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Dia-bet Med 22:554-562, 2005
19. Madhok V, Fahey T: Cardiovascular risk estimation: important but may be inaccurate. BMJ332: 1422, 2006
20. Lloyd-Jones DM, Tian L: Predicting cardiovascular risk: so what do we do now? Arch Intern Med 166:1342-1344, 2006
21. Carroll C, Naylor E, Marsden P, Dornan T: How do people with type 2 diabetes perceive and respond to cardiovascular risk? Diabet Med 20:355-360, 2003
22. Price HC, Tucker L, Griffin SJ, Holman RR: The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial. Cardiovasc Diabetol 7:21, 2008